This product is a purified rat anti-mouse Galectin-9 monoclonal antibody, clone RG9-1 (rat IgG2b, kappa), raised in rat against mouse Galectin-9 (UniProt O08573). It is validated for blocking applications and is well suited to in-vivo and functional studies in mouse models where neutralising endogenous Galectin-9 activity is the goal. The IgG2b isotype and rat host make it a practical tool for administration in immunocompetent mice, and the antibody is offered as a low-endotoxin, in-vivo-ready preparation (research grade <1 EU/mg; ultra-low grade <0.5 EU/mg) to minimise confounding innate-immune stimulation during dosing. It is available in bulk milligram-to-gram quantities to support multi-arm, multi-timepoint in-vivo experiments as well as ex-vivo blocking assays. Researchers typically identify this reagent by its clone designation, RG9-1. All material is supplied for research use only (RUO). The content below is background and general usage guidance intended for ichorbio to review prior to publication.
Galectin-9 (gene Lgals9) is a tandem-repeat member of the galectin family, comprising two carbohydrate-recognition domains joined by a linker, and binds beta-galactoside glycans on cell-surface and matrix glycoproteins. It is broadly expressed by immune, epithelial, and endothelial cells and can act both intracellularly and, upon secretion, extracellularly. Galectin-9 is best known as a ligand for TIM-3 (HAVCR2), and this interaction has been implicated in regulating T-cell responses, including the contraction of effector and Th1 populations. It has additional reported binding partners and contributes to processes such as cell adhesion, apoptosis induction in certain lymphocyte subsets, mast-cell and eosinophil biology, and modulation of both innate and adaptive immunity. Because Galectin-9 signalling is context-dependent and mediated through multiple receptors and glycan interactions, its net immunological effect varies with tissue, disease model, and cellular source.